Gross Professor of Dermatology and the director of Penn's Cutaneous Sarcoidosis & Granulomatous Disease Clinic. "Knowing that ...

Yesterday I evaluated a new patient with sarcoidosis who asked whether the disease was caused by her work as a short-order cook. The week previously, a patient wondered whether his work in a ...

Among those treated for sarcoidosis in the year following diagnosis, 60% used steroids alone, 13% nonsteroidal immunosuppressives alone, and 27% received both. About 43% of patients with sarcoidosis ...

Study objectives: Sarcoidosis is a granulomatous disorder with heterogeneous clinical manifestations, which are potentially reflective of a syndrome with different etiologies leading to similar ...

Namilumab is an anti-GM-CSF monoclonal antibody formulated to be administered once-monthly as a subcutaneous injection being investigated for the treatment of pulmonary sarcoidosis. Roivant is a ...

Namilumab is an anti-GM-CSF monoclonal antibody formulated to be administered once-monthly as a subcutaneous injection being investigated for the treatment of pulmonary sarcoidosis. In einer Welt ...

The Phase 2 RESOLVE-Lung study (NCT05314517) evaluated the efficacy and safety of namilumab, an investigational anti-GM-CSF monoclonal antibody administered once-monthly as a subcutaneous injection, ...

The Phase 2 RESOLVE-Lung study (NCT05314517) evaluated the efficacy and safety of namilumab, an investigational anti-GM-CSF monoclonal antibody administered once-monthly as a subcutaneous injection, ...